四肢关节Campanacci III期骨巨细胞瘤术前地舒单抗用药方法及停药时机研究探索

Study on the Method and Timing of Discontinuation of Denosumab before Operation for Campanacci Stage III Giant Cell Tumor of Bone in Limbs and Joints

摘要: 骨巨细胞瘤为常见原发性骨肿瘤，该疾病具有局部侵袭性强，复发率高等特征，目前研究领域针对骨巨细胞瘤的治疗已经产生了相应的干预方案，通过手术、放疗、药物干预等方案骨巨细胞瘤病情即可得到有效控制，其中地舒单抗为骨巨细胞瘤认可度较高的药物干预方案，目前地舒单抗在骨巨细胞瘤治疗中的短期安全性以及疗效已经得到了认可，但是针对药物的长期疗效，应用方式以及停药时机仍未产生明确定论，本文将对骨巨细胞瘤的概念、地舒单抗在骨巨细胞瘤治疗中的应用方式以及停药时机等相关研究进行回顾性分析，以期为故居细胞瘤术前地舒单抗的进一步应用提供参考依据。

Abstract: Giant cell tumor of bone is a common primary bone tumor with strong local invasivity and high recurrence rate. Currently, appropriate intervention programs have been developed for the treatment of giant cell tumor of bone, which can be effectively controlled through surgery, radiotherapy and drug intervention, among which denosumab is a highly recognized drug intervention program for giant cell tumor of bone. At present, the short-term safety and efficacy of denosumab in the treatment of giant cell tumor of bone have been recognized, but there is still no clear conclusion on the long-term efficacy, application mode and withdrawal time of the drug. This paper will conduct a retrospective analysis on the concept of giant cell tumor of bone, the application mode of denosumab in the treatment of giant cell tumor of bone and the withdrawal time and other relevant studies, in order to provide reference for further application of denosumab before the operation of old residence cell tumor.